ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 31.15% | 19.09% | 55.08% | 8.40% | 9.07% |
| Total Depreciation and Amortization | -75.75% | -73.92% | -20.01% | -0.70% | -8.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.94% | 38.91% | -63.20% | 52.98% | 207.01% |
| Change in Net Operating Assets | -39.07% | 896.94% | 133.25% | -103.34% | -37.39% |
| Cash from Operations | 35.59% | 48.60% | 43.52% | -66.99% | 5.00% |
| Capital Expenditure | -- | -- | -100.00% | 19.75% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -100.00% | 19.75% | -98.44% |
| Total Debt Issued | 980.00% | -18.23% | -87.00% | 450.00% | -75.00% |
| Total Debt Repaid | 74.16% | 1.90% | -482.35% | 98.07% | -3.49% |
| Issuance of Common Stock | -86.31% | -- | -- | -77.91% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -26.43% | -16.15% | -63.71% | 127.29% | 473.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 180.72% | 90.29% | -108.26% | 59.98% | 20.25% |